Growth Hormone Treatment and Papilledema : A Prospective Pilot Study
Martín-Begué, Nieves (Hospital Universitari Vall d'Hebron)
Mogas, Eduard (Hospital Universitari Vall d'Hebron)
Dod, Charlotte Wolley (Hospital Universitari Vall d'Hebron)
Alarcón, Silvia (Hospital Universitari Vall d'Hebron)
Clemente, Maria (Centro de Investigación Biomédica en Red de Enfermedades Raras)
Campos-Martorell, Ariadna (Universitat Autònoma de Barcelona)
Fábregas, Ana (Hospital Universitari Vall d'Hebron)
Yeste Fernández, Diego (Centro de Investigación Biomédica en Red de Enfermedades Raras)

Fecha:	2021
Resumen:	To investigate the incidence of pseudotumor cerebri syndrome (PTCS) in children treated with growth hormone (GH) in a paediatric hospital and to identify risk factors for this complication. Prospective pilot study of paediatric patients treated with recombinant human GH, prescribed by the Paediatric Endocrinology Department, between February 2013 and September 2017. In all these patients, a fundus examination was performed before starting treatment and 3-4 months later. Two hundred and eighty-nine patients were included, of whom 244 (84. 4%) had GH deficiency, 36 (12. 5%) had short stature associated with small for gestational age, six (2. 1%) had a mutation in the SHOX gene and three (1. 0%) had Prader-Willi syndrome. Five (1. 7%) developed papilledema, all were asymptomatic and had GH deficiency due to craniopharyngioma (n=1), polymalformative syndrome associated with hypothalamic-pituitary axis anomalies (n=2), a non-specified genetic disease with hippocampal inversion (n=1) and one with normal magnetic resonance imaging who had developed a primary PTCS years before. GH treatment is a cause of PTCS. In our series, at risk patients had GH deficiency and hypothalamic-pituitary anatomic anomalies or genetic or chromosomal diseases. Fundus examination should be systematically screened in all patients in this at-risk group, irrespective of the presence or not of symptoms.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Growth hormone treatment ; Pseudotumor cerebri syndrome ; Idiopathic intracranial hypertension ; Papilledema ; Risk factors
Publicado en:	Journal of Clinical Research in Pediatric Endocrinology, Vol. 13 (june 2021) , p. 146-151, ISSN 1308-5735

DOI: 10.4274/jcrpe.galenos.2020.2020.0007
PMID: 33006547

6 p, 162.4 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados